STA/STA

BRITISH MEDICAL JOURNAL

449.9

U. S. DEPT. OF AGRICULTURE HATIONAL AGRICULTURAL LIBRARY RECEIVED

JUL 5 1985

PROCUREMENT SECTION
CURRENT SERIAL RECORDS

SATURDAY 22 JUNE 1985

LEADING ARTICLES	
Rational drug treatment of dementia? JANE BYRNE, TOM ARIE	Prevention of hazardous drinking: the value of laboratory tests RICHARD D JOHNSON, ROGER WILLIAMS 1849
What do you work with? WR LEE	
Psychogenic cough in childhood ADMILNER 184	
The Education Act 1981 JA MACFARLANE	8 Correction: Resuscitation needed for the curriculum? 1852
	SHORT REPORTS • PRACTICE OBSERVED
Hepatitis B virus DVA in saliva, urine, and seminal fluid of carrie	ers of hepatitis B e antigen
Chronic ulceration of the leg: extent of the problem and provision	o, H C THOMAS
Relation between consumption of alcohol and fatty acids este FRANÇOIS CAMBIEN, VIVIANE VERNIER, MARTINE PECORARO, CLAUD	pasm JS ELSTON, R W ROSS RUSSELL
RICHARD, JEAN-ROGER CLAUDE	1859
IOHN BAYLISS, MICHAEL S NORELL RUDOL PH CANEDA-ANSON COLIN	heart failure: double blind comparison of captopril and prazosin REID, PHILIP POOLE-WILSON, GEORGE SUTTON
Honey in the treatment of infantile gastroenteritis I E HAFFEJEE, A	MOCSA
Do sex hormones affect colorectal cancer? MICHAEL DAVIDSON, C.	ARL N YOSHIZAWA, LAURENCE N KOLONFI. 1868
KISK profile of soldiers aged under 40 with coronary heart disease Tolerance of elemental diet administered without starter regimen	PETER LYNCH, NEIL INESON, K P JONES, A W SCOTT, I C CRAWFORD 1868 R G P REES, P P KEOHANE, G K GRIMBLE, P G FROST, H ATTRILL, D B A SILK 1869
Psoas abscess: unusual complication of effective chemotherapy for	orteratoma i maguire, srkaye 1870
Non-capsulate Haemophilus influenzae: a neglected pathogen in a	idults Pispahani, er youngs 1870
Adenocarcinoma of the ileum presenting as non-traumatic clostri	dial myonecrosis in cystic fibrosis
Intestinal perforation associated with Versinia enterocolitica infec	
₹	
Safe limits of drinking: general practitioners' views PAUL WALLAC	PETER ANDERSON 1873 E, ANNE CREMONA, PETER ANDERSON 1875 1876
MEDICAL PRACTICE	
Hospital Topics: The short life of a terminal care support team	experience at Charing Cross Hospital
Contemporary Themes: Unrecognised depression in general pract	ILLIPS, BARBARA SOUTHCOTT, IVAN WALTON
My Student Elective: An eyewitness in Bhopal MOIRA SUTCLIFFE	1883
Uccasional Paper: when do epileptic patients need treatment? Sta	rting and stopping medication D CHADWICK, E H REYNOLDS 1885 bulldog J D SPENCER, I W L BINTCLIFFE 1888
Philosophical Medical Ethics: Rights RAANAN GILLON	1890
Letter from Chicago: New epidemics GEORGE DUNEA	1892
Medicolegal: The Savage case: disciplining consultants CLARE	DYER
Medicine and Books	
Personal View JOHN M LAST	
CORRESPONDENCE—List of Contents	
	- The Week
OBITUARY	That ever more elusive green paper WILLIAM RUSSELL 1914
	Senior Hospital Staffs Conference
NEWS AND NOTES	From the HJS Conference
Views	,
Birthday Honours 1907 Medical News 1907	
BMA Notices 1909	
One Man's Burden MICHAEL O'DONNELL	

CORRESPONDENCE

HTLV-III, haemophilia, and blood transfusion		Consultation length: general practitioners' attitudes and practices		Philosophical medical ethics G D Ripley, MD; R Gillon, MRCP	1904
A L Bloom, FRCPATH, and others 1	901	R Anderson, MSC, and Ann Buxton, MB	1903	Severe extravasation injury	
Exercise and osteoporosis I Hollo, DSCIMED, and I A Gergely, MD	1002	Teenage sex J S Bradshaw, MB	1903	DAR Burd, MB, and others	1904
Male infertility	1702	Occult advanced cervical cancer C A Meanwell, MB, and others	1904	Patients who take overdoses G Halasz, MRCPSYCH, and S Jaworowski, MRANZCP	1905
D E Osborn, FRCS; F C W Wu, MRCP, and J H J Bancroft, FRCPSYCH	1902	Frozen shoulder N A Watson, FRCS	1904	"Missed pill" conception: fact or fiction? P Bye, MB	
Children not immunised for measles A G MacKenzie, MRCGP; E Pugh, MRCGP, and E Henson; R A Benson, MB	1902	Comparison of different strategies for treating duodenal ulcer DB Jones, MRCP, and others	1904	Does unemployment kill? A Scott-Samuel, MFCM	

Because we receive many more letters than we have room to publish we may shorten those that we do publish to allow readers as wide a selection as possible. In particular, when we receive several letters on the same topic we reserve the right to abridge individual letters. Our usual policy is to reserve our correspondence columns for letters commenting on issues discussed recently (within six weeks) in the BMJ.

Letters critical of a paper may be sent to the authors of the paper so that their reply may appear in the same issue. We may also forward letters that we decide not to publish to the authors of the paper on which they comment.

Letters should not exceed 400 words and should be typed double spaced and signed by all authors, who should include their main degree.

HTLV-III, haemophilia, and blood transfusion

SIR,—We are writing on behalf of the directors of the UK haemophilia reference centres to express our concern about the safety of blood and unheated blood products.

The acquired immune deficiency syndrome (AIDS) is now the most important complication of treatment for haemophilia. By the end of April 1985 over 60 American and 20 European haemophiliacs with this disorder had been reported and about half of these had died. In haemophiliacs the prevalence of antibody to the causative agent HTLV-III in the UK has been rising since 1980,1 mainly due to the use of unheated concentrate of factor VIII imported from America. However, seroconversion is also appearing in patients with haemophilia A treated only with factor VIII concentrates derived from UK plasma (Ludlum CA, Tucker J, Steel CM, et al, personal communication) and also in patients with haemophilia B treated only with locally produced factor IX concentrate. Suggestions have already been made for using heat treated dried factor VIII concentrates since HTLV-III is known to be heat sensitive.²³ A similar case could also be made for using heat treated factor IX concentrate. However, in some categories of patients cryoprecipitate was considered to be the most appropriate treatment.3

To assess the impact of these recommendations on treatment for haemophilia in the UK the directors of the 109 haemophilia centres were circulated in May 1985 with a short questionnaire; 83 replies were received (table). Many centres were using cryoprecipitate and a substantial number were still using unheated UK factor VIII concentrate, but this may have represented clearing of existing stock. Only a few centres were using heat treated factor IX concentrate, presumably because this must be purchased from commercial sources whereas the unheated material is supplied "free" from the UK manufacturers. Heat treated UK factor IX is not yet available.

The figures have some disturbing implications. Without doubt the prevalence of HTLV-III infection in the homosexual population and other potential blood donors is increasing. The safety of

cryoprecipitate and unheated UK blood products with regard to HTLV-III infection can therefore no longer be assumed, especially as these materials may need to be administered in repeated doses. Although there may be regional variations in donor positivity for HTLV-III antibody, we no longer consider that the use of cryoprecipitate or other non-heat treated concentrates is justified. Nor is this problem confined to patients with haemophilia. Although the risk from ordinary blood transfusion is still very small, it is undoubtedly increasing from the previous estimate of one in 100 000.2 Certain patients, such as those undergoing open heart surgery or those with acute leukaemias or other haematological disorders, may easily receive whole blood, platelet transfusions, cryoprecipitate, or other blood derivatives from 50 or more donors in a short space of time. The risk of HTLV-III infection in such patients could now be as high as one in 20 in certain areas of Britain.

All these considerations underline the need rapidly to introduce screening for HTLV-III antibody for all blood donations. Three commercial test kits have now been approved by the American Food and Drug Administration and, although there may be a small number of false positives, it is unreasonable to delay testing until this possibility is eliminated. Donations which are found to

be positive for HTLV-III antibodies should be discarded. The logistics of retesting, confirmatory testing, and donor counselling can then be dealt with as separate important issues, as discussed in detail in the excellent review of Osterholm et al. We believe that donors would readily accept this interim measure because, after all, they are themselves potential recipients. Although such testing will be expensive, we think that it should be implemented as soon as possible to protect recipients and to preserve public confidence in our blood transfusion services. When testing is fully implemented the role of single donor cryoprecipitate in the management of haemophilia can then be reassessed.

A L BLOOM Chairman

Haemophilia Centre, University Hospital of Wales, Cardiff CF4 4XN

C D FORBES Chairman, AIDS group

Haemophilia Centre, Glasgow Royal Infirmary Glasgow G4 0SF

C R Rizza

Secretary, UK Haemophilia Centre Directors Organisation

Haemophilia Centre, Churchill Hospital, Oxford OX3 7LJ

Factor VIII and IX concentrate use in UK

	Concentrate used			
Concentrate type	Yes	No	Comment	
Unheated commercial VIII	1	82		
Children unheated commercial VIII	0	83		
Unheated domestic VIII	33*	48		
Children unheated domestic VIII	15*			
Cryoprecipitate	73	10		
Heated commercial VIII	66	17†		
Heated domestic VIII	46	36	Not yet freely available	
Unheated domestic IX	55	12	• •	
Heated commercial IX	14	50	Two centres use both heated and unheated	
Neither IX	1	4	Presumed too few cases of haemophilia B	

^{*} Includes three centres using it only for patients with HTLV-III antibodies.

 $^{\ \, \}dagger \, Includes \, five \, Scottish \, centres \, using \, heated \, domestic \, VIII. \, Others \, include \, small \, centres \, using \, unheated \, domestic \, VIII \, or \, cryoprecipitate.$